Docetaxel Teva 20 mg, 80 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 18 June 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including breast, lung, ovarian, prostate, and head and neck cancers.
Dosage (summary)
75-100 mg/mu00b2 every 3 weeks, depending on cancer type and treatment regimen.
Onset of Action / Duration
Onset: 30 mins, Duration: 6-8 hours
Special Populations
- Hepatic impairment
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; breastfeeding should be discontinued during therapy.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Dexamethasone
- Prednisone
Contraindications
- Hypersensitivity to docetaxel
- Baseline neutrophil count < 1500 cells/mmu00b3
- Severe liver impairment
Common side effects
- Neutropenia
- Alopecia
- Nausea
- Vomiting
- Stomatitis
Counselling Points
- Monitor for signs of infection
- Avoid pregnancy
- Report any severe side effects immediately
Serious warnings
- Severe hypersensitivity reactions
- Fluid retention
- Potential for second primary malignancies
Important Disclaimer
The Docetaxel Teva 20 mg, 80 mg Concentrate for solution for infusion professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
